Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an anti‐BAFF monoclonal antibody. This phase 1, multicenter, open‐label, nonrandomized, dose‐escalation study evaluated the safety, tolerability, pharmacokinetics, pharmacodyna...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Sci
Prif Awduron: Iida, Shinsuke, Ogiya, Daisuke, Abe, Yasunobu, Taniwaki, Masafumi, Asou, Hiroya, Maeda, Kaijiro, Uenaka, Kazunori, Nagaoka, Soshi, Ishiki, Tsuyoshi, Conti, Ilaria, Tobinai, Kensei
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2016
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021044/
https://ncbi.nlm.nih.gov/pubmed/27350068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13000
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg